Meyka Pro banner
Biogen Inc.

Biogen Inc. (BIIB) Stock Overview

Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.

BIIB●NASDAQ
HealthcareDrug Manufacturers - General
$249.59
$2.46(1.00%)
U.S. Market opens in 64h 20m

Biogen Inc. (BIIB)

Meyka AI Score

Z

Key Financials

Market Cap36.9B
P/E Ratio104.72
EPS (TTM)$15.84
ROE0.02%
Fundamental Analysis

AI Price Forecasts

1 Month$254.34
3 Months$280.51
1 Year Target$169.57

BIIB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Biogen Inc. (NASDAQ: BIIB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Biogen Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BIIB on the NASDAQ shows an RSI of 51.32, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $169.57 for the NASDAQ listing.

Key metrics behind Biogen Inc.'s NASDAQ-traded stock include a P/E ratio of 104.72 and a market capitalization of 36.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BIIB on the NASDAQ.

Price Performance (NASDAQ: BIIB)

1-Day Change
1.00%
5-Day Change
-0.40%
1-Month Change
2.67%
3-Month Change
16.44%
6-Month Change
32.90%
Year-to-Date (YTD) Change
41.82%
1-Year Change
48.41%
3-Year Change
8.47%
5-Year Change
-1.04%
All-Time (Max) Change
7886.88%

Contact Information

617 679 2000
225 Binney Street, Cambridge, MA, 02142

Company Facts

75,000 Employees
IPO DateSep 17, 1991
CountryUS
Actively Trading

Frequently Asked Questions